Company intelligence / Profile preview

Azurity Pharmaceuticals

Woburn, Massachusetts, United Statesazurity.com ↗

Ownership: Private
Employees: ~582
Development stage: Commercial

Overview

Azurity specializes in providing innovative dosage forms for overlooked patients. They recently completed the acquisition of Covis Pharma in March 2025, expanding their global footprint to over 50 countries. They also received FDA approval for Danziten (nilotinib tablets), the first nilotinib with no mealtime restrictions for treating Philadelphia chromosome positive chronic myeloid leukemia.

Therapeutic areas: GastroenterologyPulmonologyCardiovascularEndocrinologyImmunologyHematologyOncologyNeurologyInfectious Diseases
Modalities: Small moleculesinnovative dosage forms
Industry: Biotech

Drug pipeline

21 assets

ferumoxytol

Approved

20 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Azurity Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Azurity Pharmaceuticals.

Explore the full profile